| Gene symbol | TTR | Synonyms | ATTR, CTS, CTS1, HEL111, HsT2651, PALB, TBPA, TTN | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | transthyretin | ||||
| GTO ID | GTC3291 |
| Trial ID | NCT05667493 |
| Disease | Transthyretin Amyloid Cardiomyopathy |
| Altered gene | TTR |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | AKCEA-TTR-LRx|Eplontersen|ION-682884|IONIS-TTR-LRx|ION-682884|Wainua |
| Location approved | US |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | An Open-Label Extension Study to Assess the Long-Term Safety of Eplontersen (ION-682884) in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) |
| Year | 2022 |
| Country | Australia|Austria|Belgium|Canada|Germany|Greece|Israel|Italy|Portugal|Spain|Sweden|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ION-682884-CS12|2022-000826-74 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||